RT Journal Article
SR Electronic
T1 Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.13.20249038
DO 10.1101/2021.01.13.20249038
A1 Crescenzo-Chaigne, Bernadette
A1 Behillil, Sylvie
A1 Enouf, Vincent
A1 Escriou, Nicolas
A1 Petres, Stephane
A1 Ungeheuer, Marie Noelle
A1 Ghosn, Jade
A1 Tubiana, Sarah
A1 Bouadma, Lila
A1 van der Werf, Sylvie
A1 Demeret, Caroline
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.13.20249038.abstract
AB Background The systemic antibody responses to SARS-CoV-2 in COVID-19 patients has been extensively studied. However, much less is known about the mucosal responses in the upper airways at the site of initial SARS-CoV-2 replication. Local antibody responses in the nasopharyngeal epithelium, that are likely to determine the course of infection, have not been analysed so far nor their correlation with antibody responses in serum.Methods The IgG and IgA antibody responses were analysed in the plasma as well as in nasopharyngeal swabs (NPS) from the first four COVID-19 patients confirmed by RT-qPCR in France. Two were pauci-symptomatic while two developed severe disease. Taking advantage of a comprehensive series of plasma and nasopharyngeal samples, we characterized their antibody profiles from the second week post symptoms onset, by using an in-house ELISA to detect anti-SARS-CoV-2 Nucleoprotein (N) IgG and IgA.Results Anti-N IgG and IgA antibodies were detected in the NPS of severe patients. Overall, the levels of IgA and IgG antibodies in plasma and NPS appeared specific to each patient.Conclusions Anti-N IgG and IgA antibodies are detected in NPS, and their levels are related to antibody levels in plasma. The two patients with severe disease exhibited different antibody profiles that may reflect different disease outcome. For the pauci-symptomatic patients, one showed a low anti-N IgG and IgA response in the plasma only, while the other one did not exhibit overt serological response.Competing Interest StatementSvdW has a patent Use of proteins and peptides coded by the genome of a novel strain of sars associated coronavirus issued, and a patent Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics pending. Professor Ghosn reports personal fees from ViiV Healthcare, Gilead Science, Janssen Cilag, and research grants from Gilead Sciences, MSD and ViiV Healthcare, outside the submitted work.Funding StatementThis work was supported by the URGENCE COVID-19 fundraising campaign of Institut Pasteur, by REACTING (Research and Action Emerging Infectious Diseases) and by the H2020 project 101003589 (RECOVER). The French Covid Cohort is funded through the Ministry of Health and Social Affairs (PHRC num.20-0424) and Ministry of Higher Education and Research dedicated COVID19 fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:French Ethic Committee CPP-Ile-de-France VI (ID-RCB: 2020-A00256-33) All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article.